DTIL Insider Trading
Insider Ownership Percentage: 4.00%
Insider Buying (Last 12 Months): $57,171.00
Insider Selling (Last 12 Months): $276,310.20
Precision BioSciences Insider Trading History Chart
This chart shows the insider buying and selling history at Precision BioSciences by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Precision BioSciences Share Price & Price History
Current Price: $4.77
Price Change: ▲ Price Increase of +0.07 (1.49%)
As of 03/31/2025 05:00 PM ET
Precision BioSciences Insider Trading History
SEC Filings (Institutional Ownership Changes) for Precision BioSciences (NASDAQ:DTIL)
37.99% of Precision BioSciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
Institutional Buying and Selling by Quarter
This chart shows the instiutional buying and selling at DTIL by year and by quarter.
Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
Precision BioSciences Institutional Trading History
Data available starting January 2016
Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Read More on Precision BioSciences
Volume
86,085 shs
Average Volume
172,082 shs
Market Capitalization
$36.59 million
P/E Ratio
79.51
Dividend Yield
N/A
Beta
1.59
Who are the company insiders with the largest holdings of Precision BioSciences?
Who are the major institutional investors of Precision BioSciences?
Which major investors are selling Precision BioSciences stock?
In the previous quarter, DTIL stock was sold by these institutional investors:
- Alyeska Investment Group L.P.
- Tejara Capital Ltd
In the previous year, company insiders that have sold Precision BioSciences company stock include:
- Michael Amoroso (CEO)
- J Jefferson Smith (Insider)
- John Alexander Kelly (CFO)
- Geno J Germano (Director)
Learn More investors selling Precision BioSciences stock.
Which major investors are buying Precision BioSciences stock?
In the previous quarter, DTIL stock was acquired by institutional investors including:
- Lynx1 Capital Management LP
- Citadel Advisors LLC
- Moloney Securities Asset Management LLC
- Dimensional Fund Advisors LP
- Tang Capital Management LLC
- Squarepoint Ops LLC
- Jane Street Group LLC
- Renaissance Technologies LLC
In the previous year, these company insiders have bought Precision BioSciences stock:
- Michael Amoroso (CEO)
- J Jefferson Smith (Insider)
- John Alexander Kelly (CFO)
Learn More investors buying Precision BioSciences stock.